---

Trans-Atlantic specialty pharma company acquired by Jazz Pharma for $700 million in 2012

EUSA Pharma was a trans-Atlantic specialty pharma company founded by CEO Bryan Morton and his team in 2006 with a focus on Critical Care and Oncology.  The company built a best in class sales and marketing infrastructure in the US and Europe based around a portfolio of high value specialty products, including Erwinaze™, a new treatment for acute lymphoblastic leukemia.  Erwinaze™ received FDA approval in 2011 and was launched successfully in the US in 2012.   

Transaction Summary

• Essex Woodlands was the founding investor of EUSA Pharma and backed a seasoned management team.
• Essex helped develop a clear business strategy to create a new trans-Atlantic specialty pharma company and supported the company through four acquisitions to achieve this goal.

• Oxford, United Kingdom


• Contact:
  Petri Vainio
  
• www.eusapharma.com
• IPO
• Acquisition
• Acquired by: Jazz Pharmaceuticals
• Exit date: April 30, 2012
• 

Related News

• EUSA Pharma Appoints Lee Morley Chief Executive & Industry Veteran Goran Ando to Board of Directors
• EUSA Pharma Spins Out of Jazz Pharma With Backing from Essex Woodlands
• EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business
• Essex Woodlands’ Bet on Bryan Morton Pays Off, as EUSA Sells to Jazz Pharma


“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA.”

Bryan Morton

Chief Executive Officer, EUSA Pharma